Expression of p53 isoforms in squamous cell carcinoma of the head and neck

被引:77
作者
Boldrup, Linda
Bourdon, Jean-Christophe
Coates, Philip J.
Sjostrom, Bjorn
Nylander, Karin
机构
[1] Umea Univ, Dept Med Biosci Pathol, SE-90185 Umea, Sweden
[2] Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland
[3] Univ Dundee, Ninewells Hosp & Med Sch, Div Pathol & Neurosci, Dundee DD1 9SY, Scotland
[4] Univ Umea Hosp, Dept Clin Sci Otorhinolaryngol, SE-90185 Umea, Sweden
关键词
p53; beta; p63; isoforms; SCCHN;
D O I
10.1016/j.ejca.2006.10.019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent data indicate that, similar to p63 and p73, several different p53 isoforms can be produced in humans through alternative initiation of translation, usage of an internal promoter and alternative splicing. These isoforms are reported to have varying functions and expressions. In squamous cell carcinoma of the head and neck (SCCHN), disruption of the p53 pathway is one of the most common genetic alterations. However, to our knowledge, no studies regarding the expression of different p53 isoforms in SCCHN have so far been performed. We screened for the expression of different p53 isoforms in SCCHN and clinically normal oral epithelia using nested RT-PCR. p53 mRNA was expressed in all tumours, all matched clinically normal tissue adjacent to the tumour and in buccal mucosa from healthy volunteers. Of the novel isoforms, p53 beta was detected in the majority of samples analysed, and all of the recently described isoforms were also detected in at least some tumour and normal epithelium samples, with the exception of Delta p53 isoforms. We conclude that p53 variant mRNAs are expressed in both normal oral stratified epithelium and SCCHN. Improvements in methodologies and reagents to detect and quantify p53 isoform expression in clinical material will be required to correlate p53 status with clinical outcomes. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:617 / 623
页数:7
相关论文
共 25 条
[1]   IMMUNOLOGICALLY DISTINCT P53 MOLECULES GENERATED BY ALTERNATIVE SPLICING [J].
ARAI, N ;
NOMURA, D ;
YOKOTA, K ;
WOLF, D ;
BRILL, E ;
SHOHAT, O ;
ROTTER, V .
MOLECULAR AND CELLULAR BIOLOGY, 1986, 6 (09) :3232-3239
[2]  
Boldrup L, 2005, INT J ONCOL, V27, P1661
[3]   p53 isoforms can regulate p53 transcriptional activity [J].
Bourdon, JC ;
Fernandes, K ;
Murray-Zmijewski, F ;
Liu, G ;
Diot, A ;
Xirodimas, DP ;
Saville, MK ;
Lane, DP .
GENES & DEVELOPMENT, 2005, 19 (18) :2122-2137
[4]   ALTERNATIVE SPLICING OF THE P53 TUMOR-SUPPRESSOR GENE IN THE MOLT-4 T-LYMPHOBLASTIC LEUKEMIA-CELL LINE [J].
CHOW, VTK ;
QUEK, HH ;
TOCK, EPC .
CANCER LETTERS, 1993, 73 (2-3) :141-148
[5]   ΔN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53 [J].
Courtois, S ;
Verhaegh, G ;
North, S ;
Luciani, MG ;
Lassus, P ;
Hibner, U ;
Oren, M ;
Hainaut, P .
ONCOGENE, 2002, 21 (44) :6722-6728
[6]   Two new p73 splice variants, γ and δ, with different transcriptional activity [J].
De Laurenzi, V ;
Costanzo, A ;
Barcaroli, D ;
Terrinoni, A ;
Falco, M ;
Annicchiarico-Petruzzeli, M ;
Levrero, M ;
Melino, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (09) :1763-1768
[7]   Transactivation-deficient p73α (p73Δexon2) inhibits apoptosis and competes with p53 [J].
Fillippovich, I ;
Sorokina, N ;
Gatei, M ;
Haupt, Y ;
Hobson, K ;
Moallem, E ;
Spring, K ;
Mould, M ;
McGuckin, MA ;
Lavin, MF ;
Khanna, KK .
ONCOGENE, 2001, 20 (04) :514-522
[8]  
Flaman JM, 1996, ONCOGENE, V12, P813
[9]   Regulation of human p53 activity and cell localization by alternative splicing [J].
Ghosh, A ;
Stewart, D ;
Matlashewski, G .
MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (18) :7987-7997
[10]   ALTERNATIVELY SPLICED P53-RNA IN TRANSFORMED AND NORMAL-CELLS OF DIFFERENT TISSUE TYPES [J].
HAN, KA ;
KULESZMARTIN, MF .
NUCLEIC ACIDS RESEARCH, 1992, 20 (08) :1979-1981